Skip to main content
Premium Trial:

Request an Annual Quote

Source MDx, Pfizer to ID Biomarkers for Cancer and Inflammatory Rx Response

NEW YORK (GenomeWeb News) — Molecular diagnostics company Source MDx today said it will work with Pfizer to uncover biomarkers linked to response and resistance to certain of the drug giant’s cancer and inflammatory candidate compounds.
 
As part of the multi-year alliance, the firms will use genomic and RNA transcription profiling to identify inflammation and cancer-related biomarkers in whole blood and circulating rare cells.
 
Validated biomarkers “will lead to joint commercial opportunities in companion diagnostics,” the companies said.
 
Source MDx stands to receive an undisclosed equity investment and technology license payment from Pfizer, plus undisclosed R&D funding over the term of the alliance.
 
Source MDx said it will also retain commercial rights to diagnostic biomarkers discovered and validated during the collaboration.
 
Financial terms of the alliance were not disclosed.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.